Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Platform Technologies Innovation Blood & Coagulation Disorders

Cytokine Storm: The Unmet Need Sigyn Hopes To Address

  • Interviews

Executive Summary

The company has developed a device for extracorporeal blood filtration that is compatible with dialysis machines.

You may also be interested in...



The Illumina Shareholder Votes Are In, And Nobody Got What They Wanted

Carl Icahn was successful in ousting Illumina’s chair, however its CEO, Francis deSouza remains. Both analysts and investors believe this could further encourage Illumina to divest Grail.

Execs On The Move: April 2023

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.  

Swedish Drug And Device To Go Head-To-Head In The GERD Space

Two Swedish companies are working on tackling GERD – one with a drug, one with a device.

Table

View full table

Topics

Tags:
Platform Technologies Innovation Blood & Coagulation Disorders
Latest Headlines

UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit

The Illumina Shareholder Votes Are In, And Nobody Got What They Wanted

UK Pro-Innovation Report Offers Promise For Medtech With MHRA/NICE Alignment

EU Regulatory Roundup, May 2023: MDR Extension Updates Resume

See All
UsernamePublicRestriction

Register

MT145244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By